Disease trajectory of <scp>SLE</scp> clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled <scp>patient‐level</scp> placebo ( <scp>Standard‐of‐Care</scp> ) data to enable <scp>model‐informed</scp> drug development-Reference-Cited by-同舟云学术

Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo ( Standard‐of‐Care ) data to enable model‐informed drug development

Published:2022-11-29 Issue:2 Volume:12 Page:180-195
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Goteti Kosalaram¹^ORCID,French Jonathan²^ORCID,Garcia Ramon²,Li Ying¹,Casset‐Semanaz Florence¹,Aydemir Aida¹,Townsend Robert¹,Mateo Cristina Vazquez¹,Studham Matthew¹,Guenther Oliver³,Kao Amy¹,Gastonguay Marc²^ORCID,Girard Pascal⁴,Benincosa Lisa¹,Venkatakrishnan Karthik¹^ORCID

Affiliation:

1. EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany) Billerica Massachusetts USA

2. Metrum Research Group Tariffville Connecticut USA

3. Merck KGaA Darmstadt Germany

4. Merck Institute of Pharmacometrics Lausanne Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12888

Reference49 articles.

1. Measures of adult systemic lupus erythematosus: updated version of British Isles lupus assessment group (BILAG 2004), European consensus lupus activity measurements (ECLAM), systemic lupus activity measure, revised (SLAM‐R), systemic lupus activity questionnaire for population studies (SLAQ), systemic lupus erythematosus disease activity index 2000 (SLEDAI‐2K), and systemic lupus international collaborating clinics/American College of Rheumatology Damage Index (SDI);Romero‐Diaz J;Arthritis Care Res,2011

2. The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment

3. What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials

4. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

5. A critical review of clinical trials in systemic lupus erythematosus

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging Enabler for Model‐Informed Precision Medicine;Clinical Pharmacology & Therapeutics;2024-01-16

2. Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus;CPT: Pharmacometrics & Systems Pharmacology;2023-12-04

3. Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective;Clinical Pharmacology & Therapeutics;2023-03-16